Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

OTHER 14NIH 4INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Lymphoid 4Other hematologic neoplasm 2

Conditions

Lymphoma, Large B-Cell, Diffuse 40Lymphoma 37Lymphoma, Follicular 33Leukemia, Lymphocytic, Chronic, B-Cell 32Lymphoma, Mantle-Cell 23Lymphoma, Non-Hodgkin 22Lymphoma, B-Cell, Marginal Zone 19Burkitt Lymphoma 19Waldenstrom Macroglobulinemia 14Leukemia 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large-Cell, Immunoblastic 10Multiple Myeloma 6Lymphoma, B-Cell 6Leukemia, Hairy Cell 6Hodgkin Disease 6Leukemia, Prolymphocytic 5Myelodysplastic Syndromes 4Lymphoma, AIDS-Related 4Dendritic Cell Sarcoma, Interdigitating 4Plasmablastic Lymphoma 3Lymphoma, Primary Effusion 3Lymphoma, Large-Cell, Anaplastic 3HIV Infections 3Epstein-Barr Virus Infections 3Neoplasms, Plasma Cell 2Neoplasms 2Neoplasm, Residual 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2

Interventions

Cyclophosphamide 7Etoposide 6fludarabine phosphate 5Methotrexate 5Filgrastim 5Vincristine 4Rituximab 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Antilymphocyte Serum 4Methylprednisolone 3Ifosfamide 3Doxorubicin 3Cytarabine 3Busulfan 3aldesleukin 2Vorinostat 2Prednisone 2Oxaliplatin 2Mycophenolic Acid 2Mercaptopurine 2Melphalan 2Dexamethasone 2Daunorubicin 2Cyclosporine 2Asparaginase 2trioctyl phosphine oxide 1sargramostim 1pevonedistat 1obatoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Dendritic Cell Sarcoma, Interdigitating × Rituximab × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT00324779 2015-09-25

Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
79 enrolled
LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT00058461 2013-10-08

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
82 enrolled
LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT00036855 2013-01-17

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
LymphoidSarcoma

Burkitt Lymphoma, Recurrence, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡